Taysha Gene Therapies

TSHANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.642 B

$5.04 +0.40%

Close of 21 Sept 2026

Revenue

$9.77M

#3158 by revenue

Earnings

-$109.0M

Loss-making

Shares outstanding

325,833,545

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#39ImmunocoreIMCR$1.66B
#40Inhibrx BiosciencesINBX$1.65B
#41Taysha Gene TherapiesTSHA$1.64B
#42Cullinan TherapeuticsCGEM$1.37B
#43ImmaticsIMTX$1.30B

What if Taysha Gene Therapies were worth as much as…

Open the what-if tool →

Gold $30.3T

$92,912.64

Per share 18,435× higher

Bitcoin $1.72T

$5,278.17

Per share 1,047× higher

Nvidia $5.48T

$16,817.97

Per share 3,337× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Taysha Gene Therapies are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.